Atea Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, and welcome to the 40th Annual JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst at the firm. Our next presenting company this morning is Atea Pharmaceuticals and to talk to us a little bit about the company is CEO, JP Sommadossi. Quick programming note, there is a Q&A session following the presentation. Simply click the ask a question button to submit and I'll work those in where appropriate.
With that, JP, thanks for joining us. Take it away.
Thank you, Eric, and thank you for the opportunity to present today at your conference. So before we begin, this is our forward-looking statement and further information can be found in our most recent filings.
Since the founding of Atea, as we discover breakthrough drugs against RNA viruses. Our platform of purine nucleotide prodrugs and bemnifosbuvir, which is the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |